MX9100884A - Eteres de 4h piridiloxina y procedimiento para su preparacion - Google Patents

Eteres de 4h piridiloxina y procedimiento para su preparacion

Info

Publication number
MX9100884A
MX9100884A MX9100884A MX9100884A MX9100884A MX 9100884 A MX9100884 A MX 9100884A MX 9100884 A MX9100884 A MX 9100884A MX 9100884 A MX9100884 A MX 9100884A MX 9100884 A MX9100884 A MX 9100884A
Authority
MX
Mexico
Prior art keywords
piridyloxine
eters
procedure
preparation
piridyloxine eters
Prior art date
Application number
MX9100884A
Other languages
English (en)
Inventor
Steven Mark Bromidge
Barry Sidney Orlek
Steven Dabbs
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of MX9100884A publication Critical patent/MX9100884A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57Nitriles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX9100884A 1990-09-01 1991-08-30 Eteres de 4h piridiloxina y procedimiento para su preparacion MX9100884A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019095A GB9019095D0 (en) 1990-09-01 1990-09-01 Novel compounds

Publications (1)

Publication Number Publication Date
MX9100884A true MX9100884A (es) 1992-05-04

Family

ID=10681500

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9100884A MX9100884A (es) 1990-09-01 1991-08-30 Eteres de 4h piridiloxina y procedimiento para su preparacion

Country Status (10)

Country Link
US (1) US5314901A (es)
EP (1) EP0546005A1 (es)
JP (1) JPH06500325A (es)
AU (1) AU8442791A (es)
GB (1) GB9019095D0 (es)
IE (1) IE913069A1 (es)
MX (1) MX9100884A (es)
PT (1) PT98824A (es)
WO (1) WO1992004323A1 (es)
ZA (1) ZA916905B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208343A (en) * 1992-03-24 1993-05-04 Warner-Lambert Company Tetrahydropyridine oxime compounds
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) * 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US11124528B2 (en) * 2017-04-27 2021-09-21 Basf Se Process for preparing optically active 2,3-dihydrothiazolo[3,2-A]pyrimidin-4-ium compounds
TWI797167B (zh) * 2018-09-28 2023-04-01 德商巴地斯顏料化工廠 用於製備光學活性嘧啶鎓化合物之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223873A (en) * 1982-04-14 1987-07-07 Francis D. King Pharmaceutically active compounds
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
GB8615785D0 (en) * 1986-06-27 1986-08-06 Beecham Group Plc Compounds
DE3789039T2 (de) * 1986-06-27 1994-06-09 Beecham Group Plc Verbrückte bicyclische N-heterocyclische Verbindungen.
US4786648A (en) * 1986-12-08 1988-11-22 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4710508A (en) * 1986-12-08 1987-12-01 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4798841A (en) * 1987-03-31 1989-01-17 Warner-Lambert Company Tetrahydropyridine oxime cholinergic agents and method of treatment
DK202388A (da) * 1987-04-15 1988-10-16 Beecham Group Plc Azabicycliske forbindelser og fremgangsmaade til fremstilling deraf
IT1203971B (it) * 1987-04-24 1989-02-23 Roussel Maestretti Spa Derivati di 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro applicazione come medicamenti
IT1222526B (it) * 1987-08-21 1990-09-05 Roussel Maestretti Spa Derivati dell' ossima della 1,2,5,6-tetraidropiridin-3-carbossaldeide,loro procedimento di preparazione e loro impiego come sostanze medicinali
IT1222529B (it) * 1987-08-21 1990-09-05 Roussel Maestretti Spa Derivati dell' ossima della 1,2,5,6-tetraidropirdin-3-carbossaldeide,loro procedimento di preparazione e loro impiego come sostanze medicinali
IL88156A (en) * 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
IT1233446B (it) * 1987-12-30 1992-04-01 Roussel Maestretti Spa Derivati della 3 piperidinocarbaldeide ossima, loro procedimento di preparazione e loro applicazione come farmaci
EP0338723B1 (en) * 1988-04-15 1993-08-04 Beecham Group Plc Novel compounds
IT1227436B (it) * 1988-10-28 1991-04-11 Roussel Maestretti Spa Derivati di 1-azabicicloalcani, loro procedimento di preparazione e loro applicazione come farmaci
US4937239A (en) * 1989-02-13 1990-06-26 Warner-Lambert Company Azabicycloalkane oxime & azabicycloalkene oxime muscarinic agents
ES2219636T3 (es) * 1989-04-13 2004-12-01 Beecham Group P.L.C. Nuevos compuestos.

Also Published As

Publication number Publication date
JPH06500325A (ja) 1994-01-13
ZA916905B (en) 1992-08-26
EP0546005A1 (en) 1993-06-16
PT98824A (pt) 1992-07-31
US5314901A (en) 1994-05-24
AU8442791A (en) 1992-03-30
GB9019095D0 (en) 1990-10-17
IE913069A1 (en) 1992-03-11
WO1992004323A1 (en) 1992-03-19

Similar Documents

Publication Publication Date Title
MX9100031A (es) Compuestos de amino silicona y procedimiento para su preparacion
MX24568A (es) 3-arilcarbonil-1h-indoles y procedimiento para su preparacion.
MX20476A (es) Composiciones de polipropileno y procedimiento para su preparacion.
MX174176B (es) Compuestos azo y procedimiento para su preparacion
MX173362B (es) Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
MX16687A (es) Compuestos de biarilo y procedimiento para su preparacion.
MX26267A (es) Aminobenzodiacepinas y procedimiento para su prepaacion.
MX9100884A (es) Eteres de 4h piridiloxina y procedimiento para su preparacion
MX9201780A (es) Eteres oximicos y procedimiento para su preparacion.
MX22255A (es) Compuestos de piridinil-quinolona y procedimiento para su preparacion.
MX9100415A (es) Piridinas substituidas y procedimiento para su obtencion
MX9100845A (es) Nuevas tienodiazepinas y procedimiento para su preparacion
MX9100743A (es) Compuestos heterociclicos y procedimiento para su preparacion
MX21243A (es) Indenoindoles y procedimiento para su preparacion.
MX9205747A (es) Pirazolinas y procedimiento para su preparacion.
MX9100811A (es) Indolonaftiridinas y procedimiento para su preparacion
MX9205821A (es) Pirimidinil- y triazinileteres y -tioeteres y procedimiento para su preparacion.
MX7829A (es) Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
MX21871A (es) Procedimiento para la preparacion de oxadiazolil fenoxialquilisoxazoles y compuestos resultantes
MX9205746A (es) Pirazolinas y procedimiento para su preparacion.
MX9101794A (es) Compuestos de trifendioxazina y procedimiento para su preparacion
MX174317B (es) Procedimiento para la preparacion de 1-hidroximetilpirazoles
MX9100779A (es) Compuestos azabiciclicos y procedimiento para su preparacion
MX9102324A (es) Pirimidilamidoximas substituidas y procedimiento para su obtencion.
MX9101592A (es) Tieno 3,2-b piran-5,7-dionas substituidas y procedimiento para su obtencion